rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Elutia, Inc.

ELUT · Nasdaq

Health CareBiotechnologyNot moving yet

ELUT stood above a rising 150-day average in 7 of the last 52 weekly readings, and has been out of that trend for the last 16 weeks. It is 15.8% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 16
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$363K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
36 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 7 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$2.0MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months14
Sale orders, 12 months0
Buyers · sellers7 · 0
WhoDidSharesTraded
Kevin RakinDirector, 10% ownerbought70,000at $1.0630 Jan 2026filed 2 Feb 2026
Guido J. NeelsDirectorbought20,000at $1.0430 Jan 2026filed 2 Feb 2026
Guido J. NeelsDirectorbought15,000at $1.0629 Jan 2026filed 29 Jan 2026
Guido J. NeelsDirectorbought15,000at $1.0628 Jan 2026filed 29 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders36+4 on the quarter
New · exited6 · 2
Reported value$13.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Nantahala Capital Management, LLCunchanged · filed 14 Aug 20263,184,947$3.1M00.0%
AIGH Capital Management LLCreduced · filed 7 Aug 20262,695,644$2.6M-899,606−25.0%
Knollwood Investment Advisory, LLCunchanged · filed 13 Aug 20262,556,724$2.5M00.0%
SILVERARC CAPITAL MANAGEMENT, LLCreduced · filed 13 Aug 20262,192,980$2.1M-305,040−12.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,142,575$1.1M+118,876+11.6%
PERKINS CAPITAL MANAGEMENT INCreduced · filed 24 Jul 2026694,094$380K-62,800−8.3%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026285,229$279K-8,167−2.8%
Corient Private Wealth LPadded · filed 12 Aug 2026253,500$248K+4,468+1.8%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026201,816$198K+119,100+144.0%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026172,446$169K+53,101+44.5%
31 Mar 2023 – 30 Jun 2026
152535Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

C. Randal Mills Company insiderPRESIDENT AND CEO · last 10 Sep 20263 · 0
Matthew Ferguson Company insiderCHIEF FINANCIAL OFFICER · last 10 Sep 20267 · 0
Michelle LeRoux Williams Company insiderCHIEF SCIENTIFIC OFFICER · last 10 Sep 20260 · 0
Brigid Makes Company insiderDirector · last 11 Jun 20262 · 0
David Colpman Company insiderDirector · last 11 Jun 20263 · 0
Guido J. Neels Company insiderDirector · last 11 Jun 20263 · 0
Kevin Rakin Company insiderDirector, 10% owner · last 11 Jun 20261 · 0
Highcape Partners Qp Ii, L.p. Company insider10% owner · last 1 Jun 20260 · 0
Highcape Partners Gp Ii, Llc Company insider10% owner · last 17 Dec 20251 · 0
Matt Zuga Company insiderDirector, 10% owner · last 29 May 20250 · 0
Maybelle Jordan Company insiderDirector · last 29 May 20250 · 0
Highcape Capital, L.p. Company insiderDirector, 10% owner · last 3 Feb 20251 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202553.7%
Operating profit marginFY 2025 · to 31 Dec 2025-219%
Free cash flow marginFY 2025 · to 31 Dec 2025-380%
Return on capital employedFY 2025 · to 31 Dec 2025-72.3%
Cash conversionFY 2025 · to 31 Dec 2025-83.9%
Research spendFY 2025 · to 31 Dec 202533.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$36.4M
Free cash flowFY 2025 · to 31 Dec 2025−$46.7M

Analyst forecasts

No analyst forecasts yet.